- Conditions
- Acute Decompensated Heart Failure
- Interventions
- Furosemide Injection Solution 8mg/mL
- Drug
- Lead sponsor
- Todd M Koelling, MD
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 77
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Acute Kidney Injury, Fluid Overload, Hypotension, Dialysis; Complications, Critical Illness
- Interventions
- Restrictive UFnet Rate Strategy, Liberal UFnet Rate Strategy
- Procedure
- Lead sponsor
- University of Pittsburgh
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 99 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 2
- States / cities
- Rochester, Minnesota • Pittsburgh, Pennsylvania
- Conditions
- Volume Overload, Kidney Failure, Respiratory Failure
- Interventions
- Share ultrasound measurement of IVC collapsibility to Nephrology Attending, Do not share ultrasound measurement of IVC collapsibility to Nephrology Attending
- Other
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2023
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Respiratory Failure, Volume Overload, Hypernatremia
- Interventions
- Supplemental metolazone diuresis, Placebo Comparator: Control-- furosemide (lasix) only
- Drug
- Lead sponsor
- Oregon Health and Science University
- Other
- Eligibility
- Not listed
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Acute Kidney Injury, Fluid Overload, Prematurity Complications, Risk Factors, Epidemiology, Chronic Kidney Disease(CKD), Hypertension
- Interventions
- Not listed
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 0 Minutes to 2 Weeks
- Enrollment
- 4,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 50
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Palo Alto, California + 45 more
- Conditions
- Congestive Heart Failure
- Interventions
- Lixivaptan, Placebo
- Drug
- Lead sponsor
- CardioKine Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 170 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2010
- U.S. locations
- 25
- States / cities
- Mobile, Alabama • Phoenix, Arizona • Jonesboro, Arkansas + 22 more
- Conditions
- Fluid Overload Pulmonary Edema, Peritoneal Dialysis Complication
- Interventions
- Lung ultrasound
- Device
- Lead sponsor
- Satellite Healthcare
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 16
- States / cities
- Daly City, California • Emeryville, California • Fremont, California + 12 more
- Conditions
- Shiga Toxin-Producing Escherichia Coli (E. Coli) Infection, Hemolytic-Uremic Syndrome
- Interventions
- Infusion of 200% maintenance fluids as balanced crystalloid IV solution, Oral fluids; infusion of up to 110% maintenance fluids as balanced crystalloid IV solution
- Other
- Lead sponsor
- University of Calgary
- Other
- Eligibility
- 9 Months to 21 Years
- Enrollment
- 1,040 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 22
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • La Jolla, California + 19 more
- Conditions
- Heart Failure
- Interventions
- The Optimal Lymph FLow (TOLF), Daily Monitoring
- Behavioral
- Lead sponsor
- Rutgers, The State University of New Jersey
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Camden, New Jersey
- Conditions
- Intradialytic Hypotension, Hypervolemia
- Interventions
- Place dialysis chair into position 3., Decrease dialysate temperature., Decrease ultrafiltration rate by 25%., Decrease ultrafiltration rate by 50%.
- Other
- Lead sponsor
- Intelomed, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Acute Kidney Injury, Fluid Overload
- Interventions
- Continuous Renal Replacement Therapy
- Other
- Lead sponsor
- Children's Hospital Medical Center, Cincinnati
- Other
- Eligibility
- 1 Year to 25 Years
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Heart Failure, Congestive Heart Failure
- Interventions
- WhiteSwell System
- Device
- Lead sponsor
- WhiteSwell, Limited
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2022
- U.S. locations
- 2
- States / cities
- Naperville, Illinois • Columbus, Ohio
- Conditions
- Hyponatremia, Euvolemia, Hypervolemia
- Interventions
- Conivaptan, placebo
- Drug
- Lead sponsor
- Cumberland Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 121 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 1
- States / cities
- Charleston, South Carolina
- Conditions
- Fluid Overload, POCUS, Lung Ultrasound, Volume Status
- Interventions
- point-of-care ultrasound (POCUS), specifically lung ultrasound (LUS), Modified Medical Research Council (mMRC) Dyspnea scale, Physical Exam
- Device · Other
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
- Conditions
- Hyponatremia With Normal Extracellular Fluid Volume
- Interventions
- lixivaptan, placebo
- Drug
- Lead sponsor
- CardioKine Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 106 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2008
- U.S. locations
- 38
- States / cities
- Mobile, Alabama • Phoenix, Arizona • Los Angeles, California + 32 more
- Conditions
- Cirrhosis
- Interventions
- Bumetanide, Furosemide
- Drug
- Lead sponsor
- Stacy Johnson
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Chronic Kidney Disease, Hypertension
- Interventions
- Diuretic augmentation (hydrochlorothiazide, chlorthalidone, furosemide, torsemide, or bumetanide)
- Drug
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 18 Years and older
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Kidney Failure, Chronic, Dietary Modification
- Interventions
- Observational Control Diet, Controlled Dietary Sodium Restriction
- Other
- Lead sponsor
- University of Illinois at Urbana-Champaign
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 1
- States / cities
- Urbana, Illinois
- Conditions
- Potential Applications for Heart Failure, Volume Overload
- Interventions
- Two-hour dwell with 10% dextrose in sterile water, Two-hour dwell with Dianeal Low-Calcium with 4.25% Dextrose
- Drug
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Chronic Kidney Disease
- Interventions
- Diuretic initiation or augmentation
- Drug
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Acute Kidney Injury, Fluid Overload
- Interventions
- Carpediem System
- Device
- Lead sponsor
- Mozarc Medical US LLC
- Industry
- Eligibility
- Not listed
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 6
- States / cities
- Iowa City, Iowa • Rochester, Minnesota • Rochester, New York + 3 more
- Conditions
- Edema, Hypervolemia, Chronic Kidney Diseases, Nephrotic Syndrome
- Interventions
- Diuretic Tuner
- Device
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Fluid Accumulation, Blood Pressure Management, End Stage Renal Disease (ESRD)
- Interventions
- Ultrafiltration
- Procedure
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Fluid Overload, Heart Failure Acute
- Interventions
- Metolazone 60 minutes prior to furosemide, Metolazone concurrently with furosemide
- Drug
- Lead sponsor
- University of Maryland, Baltimore
- Other
- Eligibility
- 18 Years to 89 Years
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland